1. Home
  2. PLX vs PEPG Comparison

PLX vs PEPG Comparison

Compare PLX & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$2.56

Market Cap

207.1M

Sector

Health Care

ML Signal

HOLD

Logo PepGen Inc.

PEPG

PepGen Inc.

HOLD

Current Price

$2.51

Market Cap

179.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLX
PEPG
Founded
1993
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
207.1M
179.4M
IPO Year
1996
2022

Fundamental Metrics

Financial Performance
Metric
PLX
PEPG
Price
$2.56
$2.51
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $10.19
AVG Volume (30 Days)
836.2K
★ 936.2K
Earning Date
08-12-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 25.61
EPS
★ 0.27
N/A
Revenue
★ $52,744,000.00
N/A
Revenue This Year
$55.77
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.46
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.65
$1.31
52 Week High
$3.19
$7.80

Technical Indicators

Market Signals
Indicator
PLX
PEPG
Relative Strength Index (RSI) 42.44 45.94
Support Level $2.21 $2.24
Resistance Level $2.75 $2.62
Average True Range (ATR) 0.10 0.23
MACD -0.02 0.03
Stochastic Oscillator 19.67 32.20

Price Performance

Historical Comparison
PLX
PEPG

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.

Share on Social Networks: